177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
Conditions: Neuroendocrine Tumors; Carcinoid Tumor; Pulmonary Carcinoid Tumor; Gastroenteropancreatic Neuroendocrine Tumor; Vipoma; Insulinoma; Gastrinoma Intervention: Drug: 177Lu-DOTATOC Sponsor: British Columbia Cancer Agency Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials